How to Buy Dianthus Therapeutics Stock
Dianthus Therapeutics Inc
Dianthus Therapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Dianthus Therapeutics stock last closed at $108.92, down 0.91% from the previous day, and has increased 468.77% in one year. It has overperformed other stocks in the Biotechnology industry by 4.78 percentage points. Dianthus Therapeutics stock is currently +502.43% from its 52-week low of $18.08, and -4.57% from its 52-week high of $114.14.
At the moment, there are 55.93M DNTH shares outstanding. The market cap of DNTH is $6.09B. In the past 24 hours, 570,000 DNTH shares were traded.
How to Buy Dianthus Therapeutics Stock
Wondering how to invest in Dianthus Therapeutics stock? Here's how.
- Figure out where to buy Dianthus Therapeutics stock: You need to choose an online brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you determine where to buy Dianthus Therapeutics stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your brokerage account: Select your method of payment and add your info.
- Research Dianthus Therapeutics stock: The Dianthus Therapeutics ticker symbol is DNTH. Is Dianthus Therapeutics stock a good investment? Should you buy shares of DNTH? How do DNTH's underlying business fundamentals look? Do top analysts think Dianthus Therapeutics is a good buy? Why has DNTH's stock price moved recently? (Hint: Our stock research website can help you figure out if DNTH is a good stock to buy).
- Make your DNTH buy order: Decide if you will purchase DNTH shares at the current market price or use a limit order to buy DNTH shares at a given price.
- Get updates on your investment in DNTH: Create a watchlist to track your position in Dianthus Therapeutics shares.
Step 1: Figure out where to buy Dianthus Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy DNTH shares.
Our recommended brokerage: eToro
Based on our research, eToro is the best stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global financial markets: From Technology to Financial Services, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro boasts a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the best brokerage, it's time to fill out some personal information so you can buy DNTH today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open a new trading account.
- Submit your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have finished signing up on stock market apps, you can securely and quickly fund your account:
Watch this video walkthrough for more details depositing funds into your brokerage account.
Step 4: Research Dianthus Therapeutics stock
After you have figured out the best place to buy Dianthus Therapeutics stock, it's crucial to analyze their stock prior to investing, so you truly comprehend the risk as well as the opportunity.
Overview of key DNTH info
Fundamentals of Dianthus Therapeutics
WallStreetZen was designed to help average investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on DNTH's stock page.
What is the fair value of DNTH stock?
You can use many financial metrics, analyses, models, and charts to gauge DNTH's intrinsic value.
Using relative valuations methods:
- DNTH may be undervalued based on its P/B ratio of 5.2x, relative to Biotechnology industry P/B ratio of 5.83x
You can do additional valuation research on DNTH's stock here.
DNTH Financial Health
Signs that DNTH is financially healthy:
- DNTH has cash burn of 155709000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the DNTH balance sheet.
- DNTH has $886.81M in cash and short term investments. This is sufficient to cover its annual cash burn of $155.71M.
- Total DNTH debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the DNTH balance sheet.
- DNTH has a low debt to equity ratio of 0.04.
Signs that DNTH is not financially healthy:
- DNTH profit margin has gone down from -2,364.1% to -10,097% in the past year.
Is DNTH stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 11 sell side analysts who give ratings on DNTH, the consensus analyst rating on Dianthus Therapeutics is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Most Recent DNTH Analyst Ratings
Sadia Rahman, a top 46% analyst from Wells Fargo initiates coverage on DNTH with a strong buy rating and announces their DNTH price target of $135.00, on Mar 19, 2026.
Steven Seedhouse, a top 13% analyst from Raymond James upgrades DNTH to a strong buy rating and raises their DNTH price target from $63.00 to $123.00, on Mar 10, 2026.
Raymond James's Steven Seedhouse upgraded their rating on Dianthus Therapeutics (NASDAQ: DNTH) from Buy to Strong Buy on 2026/03/10. The analyst also raised their price target by 95.2% from $63 to $123.
Dianthus Therapeutics reported its Q4 and FY 2025 earnings.
Following the print, Seedhouse expressed an "increasingly bullish" stance on Claseprubart.
In light of Claseprubart's further validation and development in the Phase 3 CAPTIVATE CIDP pivotal trial, the analyst raised the drug's success probability in chronic inflammatory demyelinating polyneuropathy to 80%.
Earnings Report
Dianthus Therapeutics reported:
For Q4 2025:
- Loss per share of $1.43, which missed the Zacks Consensus Estimate of $(0.98) and, by 76.5%, Q4 2024’s $(0.81).
- Revenue of $0.28M, which missed the Zacks Consensus Estimate by 45.28% and, by 78.6%, Q4 2024’s $1.33M.
For FY 2025:
- Loss per share of $4.20, compared to FY 2024’s loss of $2.55.
- Revenue of $2.04M, down 67.4% Y/Y.
Management did not provide EPS and revenue guidance in its press release.
CEO Marino Garcia commented: “It is truly exciting to be part of a company developing potential best-in-class therapies for patients suffering from severe autoimmune diseases.
“I am very proud of the impressive level of execution the Dianthus team continues to deliver against our ambitious goals.
“With claseprubart, we are building a leading neuromuscular franchise with a target product profile that aims to combine best-in-class efficacy and safety with the convenience of an infrequent, subcutaneous, self-administered autoinjector that has the potential to meaningfully shift the treatment paradigm and standard of care for more than 150,000 patients in the U.S. living with gMG, CIDP and MMN.”
Joel Beatty, a top 5% analyst from Baird maintains DNTH with a buy rating and raises their DNTH price target from $67.00 to $132.00, on Mar 10, 2026.
Bill Maughan, a bottom 9% analyst from Clear Street maintains DNTH with a strong buy rating and raises their DNTH price target from $100.00 to $130.00, on Mar 10, 2026.
Leland Gershell, a top 4% analyst from Oppenheimer maintains DNTH with a buy rating and raises their DNTH price target from $125.00 to $145.00, on Mar 9, 2026.
You can dig deeper into what analysts are saying on the Dianthus Therapeutics stock forecast page.
Metrics for Advanced DNTH Traders
DNTH Performance Numbers
Last year, DNTH revenue was $1.90M. Over the last 3 year, DNTH's revenue has gone up by -79.27% per year. This was slower than the Biotechnology industry average of 32.34%.
Dive into DNTH's earnings and revenue performance here.
Who is buying/selling DNTH?
In the last year, insiders at DNTH have bought more shares than they have sold.
Marino Garcia, CEO;Pres of DNTH, was the latest DNTH insider to buy. They bought $337,600.00 worth of DNTH shares on Aug 7, 2026.
Research more about who owns DNTH shares here.
Does DNTH stock generate passive income?
No, Dianthus Therapeutics doesn't provide an income stream by paying out dividends.
What do other investors have to say about DNTH?
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Make your DNTH buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are generally the easiest way to buy. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific price limit, place a limit order.
Hit the Open button and eToro will place your order.
If you need more help with buying stocks on eToro, click the how to video below:
Step 6: Get updates on your investment in DNTH
Now that you own some shares in DNTH, you'll want to stay up-to-date on your investment.
Make a watchlist to monitor your DNTH stock.
DNTH Feed
How to Buy Stock in Dianthus Therapeutics
To reiterate, here are the 6 steps to buy Dianthus Therapeutics stock:
- Figure out where to buy Dianthus Therapeutics stock
- Create your brokerage account
- Fund your brokerage account
- Research Dianthus Therapeutics stock
- Make your DNTH buy order
- Get updates on your investment in DNTH
If you need a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Dianthus Therapeutics, create a watchlist today.
Other "How To" Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.